Conflicts of interestH.S. was the medical expert for the study and N.B. was the advisor. H.S. and N.B. have received fees for consultation from Otsuka Pharmaceutical Co., Ltd. K.I., D.Y. and H.T. are employees of Otsuka Pharmaceutical Co., Ltd.
Data availabilityThe data that support the findings of this study are proprietary in nature and are not publicly available. However, the data are available from the corresponding author upon reasonable request.
Background: Difamilast is a selective phosphodiesterase 4 inhibitor. Phosphodiesterase 4 is involved in cytokine production linked with inflammatory disorders, including atopic dermatitis.Objective: To demonstrate the superiority of difamilast ointment 1% to vehicle in adult Japanese patients with atopic dermatitis.Methods: In this phase 3, randomized, double-blind trial, patients aged 15-70 years with an investigator global assessment score of 2 or 3 received topical difamilast ointment 1% (n = 182) or a vehicle (n = 182) twice daily for 4 weeks.
Results:The success rate in investigator global assessment score at week 4 (primary endpoint)dthe percentage of patients achieving an investigator global assessment score of 0 or 1 with $2-grade improvementdwas significantly higher with 1% difamilast than with the vehicle (38.46% vs 12.64%, respectively, P \ .0001). The success rates in $50%, $75%, and $90% improvement in overall eczema area and severity index score at week 4 followed the same trend. Difamilast at 1% provided significant mean percent improvement from baseline in overall eczema area and severity index score versus vehicle from week 1 to 4. Treatment-emergent adverse events were mostly mild or moderate and less frequent with difamilast.Limitations: Study treatment was limited to 4 weeks.
Conclusion:Difamilast ointment 1% demonstrated superiority to the vehicle and favorable safety in adult Japanese patients with atopic dermatitis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.